At the center of the sex-hormone drugs, we found EGFR, known to be transactivated by estrogen84, linked to AD in a 2022 GWAS17, increasingly implicated in AD pathogenesis85, and recently brought forward as a dual molecular target for cancer and AD86. Here, EGFR is linked to cancer.